Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pai...
Uloženo v:
| Vydáno v: | Journal of headache and pain Ročník 21; číslo 1; s. 123 - 9 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Milan
Springer Milan
17.10.2020
BMC |
| Témata: | |
| ISSN: | 1129-2369, 1129-2377, 1129-2377 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Background
Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pain burden and treatment response in patients with episodic migraine (EM) or chronic migraine (CM). The impact of galcanezumab versus placebo on TPB among patients with EM or CM was analyzed.
Methods
Patients from randomized, double-blind, placebo-controlled episodic (two 6-month studies pooled) and chronic migraine (3-month) studies received once-monthly subcutaneous injection of galcanezumab 120 mg or placebo. A post hoc analysis of TPB for a given month was calculated as severity-weighted duration by multiplying duration (hours) and maximum pain severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) of migraine for each day and summing these over the days in a month. Least square mean change from baseline in monthly TPB across Months 1–6 (EM,
N
= 444 galcanezumab,
N
= 894 placebo) and Months 1–3 (CM,
N
= 278 galcanezumab,
N
= 558 placebo) were compared using a mixed-model repeated measures model. Correlation of the Migraine Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment Scale (MIDAS) to TPB at baseline was assessed.
Results
At baseline, the duration of migraine on a given migraine headache day accounted for the greatest unique proportion of variability (EM, 57.4% and CM, 61.1%) to TPB after adjusting for frequency of migraine headache days and maximum pain severity. The decrease from baseline in monthly TPB was greater with galcanezumab than placebo for patients with EM (68.6 versus 36.2) and CM (102.6 versus 44.4). The average percent reduction of TPB from baseline was significantly greater with galcanezumab compared with placebo in patients with EM (50.8% versus 17.2%) and CM (29.7% versus 11.0%). In patients with EM and CM, TPB correlated with MSQ total score (
r
= − 0.35 and
r
= − 0.37) and MIDAS (
r
= 0.34 and
r
= 0.32).
Conclusions
Greater reduction in TPB was seen in patients with EM and CM treated with galcanezumab 120 mg once-monthly injection relative to placebo. Discussing TPB supports patient-centric conversations regarding treatment expectations when clinicians are evaluating options for migraine prevention.
Trial registration
ClinicalTrials.gov
: #
NCT02614183
(I5Q-MC-CGAG; EVOLVE-1), #
NCT02614196
(I5Q-MC-CGAH; EVOLVE-2), and #
NCT02614261
(I5Q-MC-CGAI; REGAIN) – all 3 trials were registered on 23 November 2015. |
|---|---|
| AbstractList | Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pain burden and treatment response in patients with episodic migraine (EM) or chronic migraine (CM). The impact of galcanezumab versus placebo on TPB among patients with EM or CM was analyzed.
Patients from randomized, double-blind, placebo-controlled episodic (two 6-month studies pooled) and chronic migraine (3-month) studies received once-monthly subcutaneous injection of galcanezumab 120 mg or placebo. A post hoc analysis of TPB for a given month was calculated as severity-weighted duration by multiplying duration (hours) and maximum pain severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) of migraine for each day and summing these over the days in a month. Least square mean change from baseline in monthly TPB across Months 1-6 (EM, N = 444 galcanezumab, N = 894 placebo) and Months 1-3 (CM, N = 278 galcanezumab, N = 558 placebo) were compared using a mixed-model repeated measures model. Correlation of the Migraine Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment Scale (MIDAS) to TPB at baseline was assessed.
At baseline, the duration of migraine on a given migraine headache day accounted for the greatest unique proportion of variability (EM, 57.4% and CM, 61.1%) to TPB after adjusting for frequency of migraine headache days and maximum pain severity. The decrease from baseline in monthly TPB was greater with galcanezumab than placebo for patients with EM (68.6 versus 36.2) and CM (102.6 versus 44.4). The average percent reduction of TPB from baseline was significantly greater with galcanezumab compared with placebo in patients with EM (50.8% versus 17.2%) and CM (29.7% versus 11.0%). In patients with EM and CM, TPB correlated with MSQ total score (r = - 0.35 and r = - 0.37) and MIDAS (r = 0.34 and r = 0.32).
Greater reduction in TPB was seen in patients with EM and CM treated with galcanezumab 120 mg once-monthly injection relative to placebo. Discussing TPB supports patient-centric conversations regarding treatment expectations when clinicians are evaluating options for migraine prevention.
ClinicalTrials.gov : # NCT02614183 (I5Q-MC-CGAG; EVOLVE-1), # NCT02614196 (I5Q-MC-CGAH; EVOLVE-2), and # NCT02614261 (I5Q-MC-CGAI; REGAIN) - all 3 trials were registered on 23 November 2015. Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pain burden and treatment response in patients with episodic migraine (EM) or chronic migraine (CM). The impact of galcanezumab versus placebo on TPB among patients with EM or CM was analyzed. Methods Patients from randomized, double-blind, placebo-controlled episodic (two 6-month studies pooled) and chronic migraine (3-month) studies received once-monthly subcutaneous injection of galcanezumab 120 mg or placebo. A post hoc analysis of TPB for a given month was calculated as severity-weighted duration by multiplying duration (hours) and maximum pain severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) of migraine for each day and summing these over the days in a month. Least square mean change from baseline in monthly TPB across Months 1–6 (EM, N = 444 galcanezumab, N = 894 placebo) and Months 1–3 (CM, N = 278 galcanezumab, N = 558 placebo) were compared using a mixed-model repeated measures model. Correlation of the Migraine Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment Scale (MIDAS) to TPB at baseline was assessed. Results At baseline, the duration of migraine on a given migraine headache day accounted for the greatest unique proportion of variability (EM, 57.4% and CM, 61.1%) to TPB after adjusting for frequency of migraine headache days and maximum pain severity. The decrease from baseline in monthly TPB was greater with galcanezumab than placebo for patients with EM (68.6 versus 36.2) and CM (102.6 versus 44.4). The average percent reduction of TPB from baseline was significantly greater with galcanezumab compared with placebo in patients with EM (50.8% versus 17.2%) and CM (29.7% versus 11.0%). In patients with EM and CM, TPB correlated with MSQ total score ( r = − 0.35 and r = − 0.37) and MIDAS ( r = 0.34 and r = 0.32). Conclusions Greater reduction in TPB was seen in patients with EM and CM treated with galcanezumab 120 mg once-monthly injection relative to placebo. Discussing TPB supports patient-centric conversations regarding treatment expectations when clinicians are evaluating options for migraine prevention. Trial registration ClinicalTrials.gov : # NCT02614183 (I5Q-MC-CGAG; EVOLVE-1), # NCT02614196 (I5Q-MC-CGAH; EVOLVE-2), and # NCT02614261 (I5Q-MC-CGAI; REGAIN) – all 3 trials were registered on 23 November 2015. Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pain burden and treatment response in patients with episodic migraine (EM) or chronic migraine (CM). The impact of galcanezumab versus placebo on TPB among patients with EM or CM was analyzed.BACKGROUNDFocus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pain burden and treatment response in patients with episodic migraine (EM) or chronic migraine (CM). The impact of galcanezumab versus placebo on TPB among patients with EM or CM was analyzed.Patients from randomized, double-blind, placebo-controlled episodic (two 6-month studies pooled) and chronic migraine (3-month) studies received once-monthly subcutaneous injection of galcanezumab 120 mg or placebo. A post hoc analysis of TPB for a given month was calculated as severity-weighted duration by multiplying duration (hours) and maximum pain severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) of migraine for each day and summing these over the days in a month. Least square mean change from baseline in monthly TPB across Months 1-6 (EM, N = 444 galcanezumab, N = 894 placebo) and Months 1-3 (CM, N = 278 galcanezumab, N = 558 placebo) were compared using a mixed-model repeated measures model. Correlation of the Migraine Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment Scale (MIDAS) to TPB at baseline was assessed.METHODSPatients from randomized, double-blind, placebo-controlled episodic (two 6-month studies pooled) and chronic migraine (3-month) studies received once-monthly subcutaneous injection of galcanezumab 120 mg or placebo. A post hoc analysis of TPB for a given month was calculated as severity-weighted duration by multiplying duration (hours) and maximum pain severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) of migraine for each day and summing these over the days in a month. Least square mean change from baseline in monthly TPB across Months 1-6 (EM, N = 444 galcanezumab, N = 894 placebo) and Months 1-3 (CM, N = 278 galcanezumab, N = 558 placebo) were compared using a mixed-model repeated measures model. Correlation of the Migraine Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment Scale (MIDAS) to TPB at baseline was assessed.At baseline, the duration of migraine on a given migraine headache day accounted for the greatest unique proportion of variability (EM, 57.4% and CM, 61.1%) to TPB after adjusting for frequency of migraine headache days and maximum pain severity. The decrease from baseline in monthly TPB was greater with galcanezumab than placebo for patients with EM (68.6 versus 36.2) and CM (102.6 versus 44.4). The average percent reduction of TPB from baseline was significantly greater with galcanezumab compared with placebo in patients with EM (50.8% versus 17.2%) and CM (29.7% versus 11.0%). In patients with EM and CM, TPB correlated with MSQ total score (r = - 0.35 and r = - 0.37) and MIDAS (r = 0.34 and r = 0.32).RESULTSAt baseline, the duration of migraine on a given migraine headache day accounted for the greatest unique proportion of variability (EM, 57.4% and CM, 61.1%) to TPB after adjusting for frequency of migraine headache days and maximum pain severity. The decrease from baseline in monthly TPB was greater with galcanezumab than placebo for patients with EM (68.6 versus 36.2) and CM (102.6 versus 44.4). The average percent reduction of TPB from baseline was significantly greater with galcanezumab compared with placebo in patients with EM (50.8% versus 17.2%) and CM (29.7% versus 11.0%). In patients with EM and CM, TPB correlated with MSQ total score (r = - 0.35 and r = - 0.37) and MIDAS (r = 0.34 and r = 0.32).Greater reduction in TPB was seen in patients with EM and CM treated with galcanezumab 120 mg once-monthly injection relative to placebo. Discussing TPB supports patient-centric conversations regarding treatment expectations when clinicians are evaluating options for migraine prevention.CONCLUSIONSGreater reduction in TPB was seen in patients with EM and CM treated with galcanezumab 120 mg once-monthly injection relative to placebo. Discussing TPB supports patient-centric conversations regarding treatment expectations when clinicians are evaluating options for migraine prevention.ClinicalTrials.gov : # NCT02614183 (I5Q-MC-CGAG; EVOLVE-1), # NCT02614196 (I5Q-MC-CGAH; EVOLVE-2), and # NCT02614261 (I5Q-MC-CGAI; REGAIN) - all 3 trials were registered on 23 November 2015.TRIAL REGISTRATIONClinicalTrials.gov : # NCT02614183 (I5Q-MC-CGAG; EVOLVE-1), # NCT02614196 (I5Q-MC-CGAH; EVOLVE-2), and # NCT02614261 (I5Q-MC-CGAI; REGAIN) - all 3 trials were registered on 23 November 2015. Abstract Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A composite measure of total pain burden (TPB; frequency, severity, and duration) may provide a more comprehensive characterization of pain burden and treatment response in patients with episodic migraine (EM) or chronic migraine (CM). The impact of galcanezumab versus placebo on TPB among patients with EM or CM was analyzed. Methods Patients from randomized, double-blind, placebo-controlled episodic (two 6-month studies pooled) and chronic migraine (3-month) studies received once-monthly subcutaneous injection of galcanezumab 120 mg or placebo. A post hoc analysis of TPB for a given month was calculated as severity-weighted duration by multiplying duration (hours) and maximum pain severity (0 = none, 1 = mild, 2 = moderate, 3 = severe) of migraine for each day and summing these over the days in a month. Least square mean change from baseline in monthly TPB across Months 1–6 (EM, N = 444 galcanezumab, N = 894 placebo) and Months 1–3 (CM, N = 278 galcanezumab, N = 558 placebo) were compared using a mixed-model repeated measures model. Correlation of the Migraine Specific Quality of Life Questionnaire (MSQ) and Migraine Disability Assessment Scale (MIDAS) to TPB at baseline was assessed. Results At baseline, the duration of migraine on a given migraine headache day accounted for the greatest unique proportion of variability (EM, 57.4% and CM, 61.1%) to TPB after adjusting for frequency of migraine headache days and maximum pain severity. The decrease from baseline in monthly TPB was greater with galcanezumab than placebo for patients with EM (68.6 versus 36.2) and CM (102.6 versus 44.4). The average percent reduction of TPB from baseline was significantly greater with galcanezumab compared with placebo in patients with EM (50.8% versus 17.2%) and CM (29.7% versus 11.0%). In patients with EM and CM, TPB correlated with MSQ total score (r = − 0.35 and r = − 0.37) and MIDAS (r = 0.34 and r = 0.32). Conclusions Greater reduction in TPB was seen in patients with EM and CM treated with galcanezumab 120 mg once-monthly injection relative to placebo. Discussing TPB supports patient-centric conversations regarding treatment expectations when clinicians are evaluating options for migraine prevention. Trial registration ClinicalTrials.gov : # NCT02614183 (I5Q-MC-CGAG; EVOLVE-1), # NCT02614196 (I5Q-MC-CGAH; EVOLVE-2), and # NCT02614261 (I5Q-MC-CGAI; REGAIN) – all 3 trials were registered on 23 November 2015. |
| ArticleNumber | 123 |
| Author | Ailani, Jessica Rettiganti, Mallikarjuna Andrews, J. Scott Nicholson, Robert A. |
| Author_xml | – sequence: 1 givenname: Jessica surname: Ailani fullname: Ailani, Jessica email: Jessica.X.Ailani@gunet.georgetown.edu organization: Georgetown University – sequence: 2 givenname: J. Scott surname: Andrews fullname: Andrews, J. Scott organization: Eli Lilly and Company – sequence: 3 givenname: Mallikarjuna surname: Rettiganti fullname: Rettiganti, Mallikarjuna organization: Eli Lilly and Company – sequence: 4 givenname: Robert A. surname: Nicholson fullname: Nicholson, Robert A. organization: Eli Lilly and Company |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33069214$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9UltrFDEUHqRiL_oHfJA8VtjRZDKXjA9CKWtdWCyI9jVkkpPdLJlkTDKK_Y_-J9NuW6wPfTqHk-8C-b7j4sB5B0XxmuB3hLD2fSSY9HWJK1xiQnpcds-KI0Kqvqxo1x087G1_WBzHuMMZSVnzojikFLd9Reqj4s9qnIRMyGu0EVYKB9fzKAbkHUo-CYsmYRwa5qDAfUDaOGXcJiId_IimrYiAKArCKT-aa1ALpPw8WCgHm5ELNFkhYfCl9C4Fby0oFNOsDESUVSeRDLgU0S-TtggmE70yEvmA5DZ4l9fRbEL2B3S6vLpcXy1LskB3W7VA2RZ9XV6crb6gFIyw8e3L4rnOE17dzZPi-6flt_PP5fryYnV-ti5lQ6pUDsMgatW0cug1Y7XUve4YJXoQPUADrZJUtbVsJaaKSUI1wbpuVCeYUFKpip4Uq72u8mLHp2BGEX5zLwy_Pfiw4SIkIy3wpgZN626gDahaaM0kE1jQvuuVhApw1vq415rmYYR8zF8l7CPRxy_ObPnG_-Rd0zJGbwRO7wSC_zFDTHw0UYK1OUw_R17VTYX7nuE2Q9_86_Vgct-HDGB7gAw-xgCaS5NyTDf5CWM5wfymenxfPZ4LxW-rx7tMrf6j3qs_SaJ7Usxgt4HAd34OLmf3FOsvj_jvUQ |
| CitedBy_id | crossref_primary_10_1080_14656566_2022_2102420 crossref_primary_10_1186_s10194_025_02013_3 crossref_primary_10_3390_toxins16020106 crossref_primary_10_1007_s12325_022_02233_y crossref_primary_10_1186_s10194_021_01215_9 crossref_primary_10_3389_fneur_2022_846717 crossref_primary_10_1007_s40120_021_00236_5 crossref_primary_10_3390_neurolint15010017 crossref_primary_10_1007_s40261_021_01115_5 crossref_primary_10_1111_head_14404 crossref_primary_10_1186_s10194_022_01436_6 crossref_primary_10_1007_s40120_022_00410_3 crossref_primary_10_1177_03331024221089567 crossref_primary_10_3389_fneur_2022_955298 |
| Cites_doi | 10.1016/S1474-4422(18)30322-3 10.1186/s10194-018-0946-z 10.1046/j.1468-2982.2000.00117.x 10.1046/j.1468-2982.1999.019002107.x 10.1016/S0140-6736(18)30478-1 10.1001/jamaneurol.2018.1212 10.1186/s10194-020-01143-0 10.1186/s10194-020-01102-9 10.1186/s10194-019-0993-0 10.1177/0333102418779543 10.1111/j.1526-4610.2005.05097.x 10.1046/j.1526-4610.1998.3804295.x 10.1212/WNL.0000000000006640 10.1007/s10194-012-0460-7 10.1111/j.1526-4610.2012.02223.x 10.1097/JOM.0b013e31803b9510 10.1177/0333102411410610 10.1177/0333102413485658 10.1177/0333102410381145 10.1177/0333102414552532 10.1212/WNL.59.5_suppl_2.S8 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 |
| Copyright_xml | – notice: The Author(s) 2020 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s10194-020-01190-7 |
| DatabaseName | SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1129-2377 |
| EndPage | 9 |
| ExternalDocumentID | oai_doaj_org_article_54ef347b35ed4aff8c8a0a3979dce2e0 PMC7568830 33069214 10_1186_s10194_020_01190_7 |
| Genre | Randomized Controlled Trial Clinical Trial, Phase III Journal Article |
| GrantInformation_xml | – fundername: Eli Lilly and Company funderid: http://dx.doi.org/10.13039/100004312 – fundername: ; |
| GroupedDBID | --- -5E -5G -A0 -BR -Y2 -~C .86 0R~ 123 1SB 29K 2P1 2VQ 36B 3V. 4.4 40G 53G 5VS 67Z 6NX 7RV 7X7 88E 8AO 8FI 8FJ 8TC 8UJ AAFWJ AAIAL AAJSJ AAKDD AAKKN AANXM AAWTL AAYZH ABEEZ ABIVO ABMNI ABTEG ABUWG ACACY ACGFS ACOMO ACPRK ACULB ADBBV ADINQ ADKPE ADQRH ADRAZ ADRFC AENEX AFBBN AFGXO AFKRA AFLOW AFPKN AGJBK AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS AZQEC BA0 BAPOH BAWUL BCNDV BENPR BFQNJ BGNMA BKEYQ BMC BPHCQ BVXVI C24 C6C CAG CCPQU COF CS3 CSCUP D-I DIK DL5 DU5 DWQXO EBLON EBS EJD EMB EMOBN EX3 F5P FYUFA GNUQQ GROUPED_DOAJ GXS H13 HF~ HG6 HMCUK HYE HZ~ I09 IHE IXC IXE IZQ I~X KDC KOV KPH KQ8 LAS M1P M2M M48 M4Y M~E NAPCQ NB0 NU0 O9- OAM OK1 PGMZT PIMPY PQQKQ PROAC PSQYO PSYQQ PZZ Q2X RNS ROL RPM RPX RRX RSV S1Z S27 SDH SMD SOJ SV3 T13 TSK U2A UKHRP VC2 WJK WOW Z7U Z82 Z87 ~KM AASML AAYXX ADUKV CITATION CGR CUY CVF ECM EIF NPM 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c512t-bbba4d56cb9f884cf9f7831fba9ee5e6dc3d64c6c03d8c13f10f45d7a8adcdd23 |
| IEDL.DBID | C24 |
| ISICitedReferencesCount | 16 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000578491000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1129-2369 1129-2377 |
| IngestDate | Fri Oct 03 12:34:26 EDT 2025 Tue Nov 04 01:57:09 EST 2025 Thu Sep 04 19:09:46 EDT 2025 Mon Jul 21 05:49:35 EDT 2025 Tue Nov 18 21:54:00 EST 2025 Sat Nov 29 04:12:34 EST 2025 Fri Feb 21 02:37:09 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Chronic migraine Prevention Headache Burden of illness Pain Migraine Clinical trial Galcanezumab |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c512t-bbba4d56cb9f884cf9f7831fba9ee5e6dc3d64c6c03d8c13f10f45d7a8adcdd23 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://link.springer.com/10.1186/s10194-020-01190-7 |
| PMID | 33069214 |
| PQID | 2452099806 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_54ef347b35ed4aff8c8a0a3979dce2e0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7568830 proquest_miscellaneous_2452099806 pubmed_primary_33069214 crossref_citationtrail_10_1186_s10194_020_01190_7 crossref_primary_10_1186_s10194_020_01190_7 springer_journals_10_1186_s10194_020_01190_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-17 |
| PublicationDateYYYYMMDD | 2020-10-17 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | Milan |
| PublicationPlace_xml | – name: Milan – name: England |
| PublicationSubtitle | Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache" |
| PublicationTitle | Journal of headache and pain |
| PublicationTitleAbbrev | J Headache Pain |
| PublicationTitleAlternate | J Headache Pain |
| PublicationYear | 2020 |
| Publisher | Springer Milan BMC |
| Publisher_xml | – name: Springer Milan – name: BMC |
| References | Martelletti, Schwedt, Lanteri-Minet, Quintana, Carboni, Diener (CR9) 2018; 19 Jhingran, Osterhaus, Miller, Lee, Kirchdoetfer (CR16) 1998; 38 Skljarevski, Matharu, Millen, Ossipov, Kim, Yang (CR13) 2018; 38 Hawkins, Wang, Rupnow (CR1) 2007; 49 Payne, Varon, Kawata, Yeomans, Wilcox, Manack (CR3) 2011; 31 Adams, Serrano, Buse, Reed, Marske, Fanning, Lipton (CR6) 2015; 35 (CR7) 2018; 17 Detke, Goadsby, Wang, Friedman, Selzler, Aurora (CR12) 2018; 91 Tfelt-Hansen, Block, Dahlöf (CR18) 2000; 20 CR19 Bloudek, Stokes, Buse, Wilcox, Lipton, Goadsby (CR4) 2012; 13 Leonardi, Raggi (CR10) 2019; 20 McCrory, Gray, Tfelt-Hansen, Steiner, Taylor (CR20) 2005; 45 CR11 Ornello, Casalena, Frattale (CR21) 2020; 21 Stewart, Lipton, Kolodner, Liberman, Sawyer (CR17) 1999; 19 Buse, Manack, Fanning, Serrano, Reed, Turkel, Lipton (CR5) 2012; 52 (CR15) 2013; 33 Russo, Silvestro, di Clemente (CR22) 2020; 21 Blumenfeld, Varon, Wilcox, Buse, Kawata, Manack (CR2) 2011; 31 Dodick (CR8) 2018; 391 Stauffer, Dodick, Zhang, Carter, Ailani, Conley (CR14) 2018; 75 DC McCrory (1190_CR20) 2005; 45 M Leonardi (1190_CR10) 2019; 20 Headache Classification Committee of the International Headache Society (IHS) (1190_CR15) 2013; 33 DC Buse (1190_CR5) 2012; 52 1190_CR19 AM Adams (1190_CR6) 2015; 35 GBD 2016 Headache Collaborators (1190_CR7) 2018; 17 DW Dodick (1190_CR8) 2018; 391 K Hawkins (1190_CR1) 2007; 49 P Martelletti (1190_CR9) 2018; 19 R Ornello (1190_CR21) 2020; 21 HC Detke (1190_CR12) 2018; 91 WF Stewart (1190_CR17) 1999; 19 P Tfelt-Hansen (1190_CR18) 2000; 20 1190_CR11 A Blumenfeld (1190_CR2) 2011; 31 V Skljarevski (1190_CR13) 2018; 38 KA Payne (1190_CR3) 2011; 31 A Russo (1190_CR22) 2020; 21 VL Stauffer (1190_CR14) 2018; 75 LM Bloudek (1190_CR4) 2012; 13 P Jhingran (1190_CR16) 1998; 38 |
| References_xml | – volume: 17 start-page: 954 year: 2018 end-page: 976 ident: CR7 article-title: Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 publication-title: Lancet Neuro doi: 10.1016/S1474-4422(18)30322-3 – volume: 19 start-page: 115 year: 2018 ident: CR9 article-title: My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed publication-title: J Headache Pain. doi: 10.1186/s10194-018-0946-z – volume: 20 start-page: 765 year: 2000 end-page: 786 ident: CR18 article-title: International headache society clinical trials subcommittee. Guidelines for controlled trials of drugs in migraine: second edition publication-title: Cephalalgia doi: 10.1046/j.1468-2982.2000.00117.x – ident: CR19 – volume: 19 start-page: 107 year: 1999 end-page: 114 ident: CR17 article-title: Reliability of the migraine disability assessment score in a population-based sample of headache sufferers publication-title: Cephalalgia doi: 10.1046/j.1468-2982.1999.019002107.x – volume: 391 start-page: 1315 year: 2018 end-page: 1330 ident: CR8 article-title: Migraine publication-title: Lancet. doi: 10.1016/S0140-6736(18)30478-1 – volume: 75 start-page: 1080 year: 2018 end-page: 1088 ident: CR14 article-title: Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2018.1212 – volume: 21 start-page: 69 year: 2020 ident: CR22 article-title: Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience publication-title: J Headache Pain doi: 10.1186/s10194-020-01143-0 – volume: 21 start-page: 32 year: 2020 ident: CR21 article-title: Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy publication-title: J Headache Pain doi: 10.1186/s10194-020-01102-9 – volume: 20 start-page: 41 issue: 1 year: 2019 ident: CR10 article-title: A narrative review on the burden of migraine: when the burden is the impact on people's life publication-title: J Headache Pain doi: 10.1186/s10194-019-0993-0 – ident: CR11 – volume: 38 start-page: 1442 year: 2018 end-page: 1454 ident: CR13 article-title: Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial publication-title: Cephalalgia. doi: 10.1177/0333102418779543 – volume: 45 start-page: 459 year: 2005 end-page: 465 ident: CR20 article-title: Methodological issues in systematic reviews of headache trials: adapting historical diagnostic classifications and outcome measures to present-day standards publication-title: Headache doi: 10.1111/j.1526-4610.2005.05097.x – volume: 38 start-page: 295 year: 1998 end-page: 302 ident: CR16 article-title: Development and validation of the migraine specific quality-of-life questionnaire publication-title: Headache. doi: 10.1046/j.1526-4610.1998.3804295.x – volume: 91 start-page: e2211 year: 2018 end-page: e2221 ident: CR12 article-title: Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study publication-title: Neurology. doi: 10.1212/WNL.0000000000006640 – volume: 13 start-page: 361 year: 2012 end-page: 378 ident: CR4 article-title: Cost of healthcare for patients with migraine in five European countries: results from The International Burden of Migraine Study (IBMS) publication-title: J Headache Pain. doi: 10.1007/s10194-012-0460-7 – volume: 52 start-page: 1456 year: 2012 end-page: 1470 ident: CR5 article-title: Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study publication-title: Headache doi: 10.1111/j.1526-4610.2012.02223.x – volume: 49 start-page: 368 year: 2007 end-page: 374 ident: CR1 article-title: Indirect cost burden of migraine in the United States publication-title: J Occup Environ Med doi: 10.1097/JOM.0b013e31803b9510 – volume: 31 start-page: 1116 year: 2011 end-page: 1130 ident: CR3 article-title: The International Burden of Migraine Study (IBMS): study design, methodology, and baseline cohort characteristics publication-title: Cephalalgia. doi: 10.1177/0333102411410610 – volume: 33 start-page: 629 year: 2013 end-page: 808 ident: CR15 article-title: The international classification of headache disorders, 3rd edition (beta version) publication-title: Cephalalgia doi: 10.1177/0333102413485658 – volume: 31 start-page: 301 year: 2011 end-page: 305 ident: CR2 article-title: Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study publication-title: Cephalalgia. doi: 10.1177/0333102410381145 – volume: 35 start-page: 563 year: 2015 end-page: 578 ident: CR6 article-title: The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results publication-title: Cephalalgia. doi: 10.1177/0333102414552532 – volume: 49 start-page: 368 year: 2007 ident: 1190_CR1 publication-title: J Occup Environ Med doi: 10.1097/JOM.0b013e31803b9510 – volume: 19 start-page: 115 year: 2018 ident: 1190_CR9 publication-title: J Headache Pain. doi: 10.1186/s10194-018-0946-z – volume: 38 start-page: 295 year: 1998 ident: 1190_CR16 publication-title: Headache. doi: 10.1046/j.1526-4610.1998.3804295.x – volume: 20 start-page: 41 issue: 1 year: 2019 ident: 1190_CR10 publication-title: J Headache Pain doi: 10.1186/s10194-019-0993-0 – volume: 31 start-page: 1116 year: 2011 ident: 1190_CR3 publication-title: Cephalalgia. doi: 10.1177/0333102411410610 – volume: 21 start-page: 32 year: 2020 ident: 1190_CR21 publication-title: J Headache Pain doi: 10.1186/s10194-020-01102-9 – volume: 391 start-page: 1315 year: 2018 ident: 1190_CR8 publication-title: Lancet. doi: 10.1016/S0140-6736(18)30478-1 – volume: 21 start-page: 69 year: 2020 ident: 1190_CR22 publication-title: J Headache Pain doi: 10.1186/s10194-020-01143-0 – volume: 52 start-page: 1456 year: 2012 ident: 1190_CR5 publication-title: Headache doi: 10.1111/j.1526-4610.2012.02223.x – volume: 91 start-page: e2211 year: 2018 ident: 1190_CR12 publication-title: Neurology. doi: 10.1212/WNL.0000000000006640 – volume: 13 start-page: 361 year: 2012 ident: 1190_CR4 publication-title: J Headache Pain. doi: 10.1007/s10194-012-0460-7 – volume: 35 start-page: 563 year: 2015 ident: 1190_CR6 publication-title: Cephalalgia. doi: 10.1177/0333102414552532 – volume: 75 start-page: 1080 year: 2018 ident: 1190_CR14 publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2018.1212 – volume: 19 start-page: 107 year: 1999 ident: 1190_CR17 publication-title: Cephalalgia doi: 10.1046/j.1468-2982.1999.019002107.x – volume: 45 start-page: 459 year: 2005 ident: 1190_CR20 publication-title: Headache doi: 10.1111/j.1526-4610.2005.05097.x – volume: 33 start-page: 629 year: 2013 ident: 1190_CR15 publication-title: Cephalalgia doi: 10.1177/0333102413485658 – volume: 38 start-page: 1442 year: 2018 ident: 1190_CR13 publication-title: Cephalalgia. doi: 10.1177/0333102418779543 – volume: 20 start-page: 765 year: 2000 ident: 1190_CR18 publication-title: Cephalalgia doi: 10.1046/j.1468-2982.2000.00117.x – ident: 1190_CR11 – volume: 17 start-page: 954 year: 2018 ident: 1190_CR7 publication-title: Lancet Neuro doi: 10.1016/S1474-4422(18)30322-3 – volume: 31 start-page: 301 year: 2011 ident: 1190_CR2 publication-title: Cephalalgia. doi: 10.1177/0333102410381145 – ident: 1190_CR19 doi: 10.1212/WNL.59.5_suppl_2.S8 |
| SSID | ssj0020385 |
| Score | 2.325445 |
| Snippet | Background
Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive... Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique, additive burden. A... Abstract Background Focus on the frequency of migraine pain may undervalue the total burden of migraine as pain duration and severity may present unique,... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 123 |
| SubjectTerms | Antibodies, Monoclonal, Humanized Burden of illness Chronic migraine Double-Blind Method Galcanezumab Headache Humans Internal Medicine Medicine Medicine & Public Health Migraine Migraine Disorders - drug therapy Neurology Pain Pain Medicine Quality of Life Research Article Treatment Outcome |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQCiEuiDfhpUHiAKIWSZyHw21BXVhpKQhBtTfLz91IbVI1LYf9j_wnxk5SUUDLhVvTuE3s-ZyZycx8Q8jzPHYxr7ihZWxjmuVcU5m4lGrmlJTamiT0OpyflLMZPz2tPv_S6svnhPX0wP3Cvc4z61hWKpZbk0nnuOYylj4aZbRNbfDW0eoZnanB1fLxrtBWJa1oyopqLJfhhS-aSzwdbuoTsnwhdbmnkgJz_9_MzT-zJn8LnQaNdHST3BhMSTjsp3CLXLHNbXLt4xAsv0N-HIcKSGgdoBrAJbQX26VU0DawadHmhpWsG1ChjuENhOB1c9aBLziB1TlqN2CAmsy0y_rCmgmYdqsWlio0TPEoJHOplg657gtroOtzEgH_daBr7cC_5wW7qrsWbwvaNeiejReW9ZnvTmHhxXT-6WQ-pckEhk_pBPCy8GX6_vB4BqGvSPfyLvl2NP367gMdujdQjUbEhiqlZGbyQqvKcZ5pV7mSswQhUFmb28JoZopMFzpmhuuEuSR2WW5KyaXRxqTsHjlo2sY-IJBrdBslDpWuylKEgSoQYbHzhUr4AIkjkowCFHqgNvcdNhYiuDi8EL3QBQpdBKGLMiKvdr9Z9cQel45-63GxG-lJucMXCFUxQFX8C6oReTaiSuAm9pEZFH277YQPf6OpzuMiIvd7lO0uxdCpq9Iki0i5h7-9e9k_09TngSi8zAvO_fJMRqSK4QnVXTLXh_9jro_I9dRvMZ_7Uz4mB5v11j4hV_X3Td2tn4bN-hOpiURV priority: 102 providerName: Directory of Open Access Journals |
| Title | Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials) |
| URI | https://link.springer.com/article/10.1186/s10194-020-01190-7 https://www.ncbi.nlm.nih.gov/pubmed/33069214 https://www.proquest.com/docview/2452099806 https://pubmed.ncbi.nlm.nih.gov/PMC7568830 https://doaj.org/article/54ef347b35ed4aff8c8a0a3979dce2e0 |
| Volume | 21 |
| WOSCitedRecordID | wos000578491000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1129-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020385 issn: 1129-2369 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVAVX databaseName: Springer Nature OA Free Journals customDbUrl: eissn: 1129-2377 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020385 issn: 1129-2369 databaseCode: C24 dateStart: 20000701 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF7RghAX3oXwiAaJA4hYsr1-rLmVKoVKJSAEUW7WPlNLiTeKEw79j_wnZtd2pEBVCW5JvLHHnm93Zj3zzRDyOg1NyAqmgjzUYZCkTAY8MnEgqRGcS60i3-twep5PJmw2K752pLCmz3bvQ5J-pfbTmmWO7Ba5MraxS6RyBOj8gNxMI1Y4XJ84jkO3zXKxLt9SJS6CmGZFT5W58hx75shX7b_K1fw7Y_KPsKm3Rqf3_u8-7pO7nfcJxy1cHpAbun5Ibn_u4uuPyK8zT5oEawAtBz51fbldcgG2ho1FNx1WvKpBeOrDe_Dx7nregOOowOoCDSJQQOOn7LK61GoEym7FQgcC5cRvPv9L2KBLj19oBU2bxgh41q7CawPu1TDoVdVYFAvsGmRbwBeW1dw1tNDwZjz9cj4dB9EIuk_xCPCy8G388fhsAr4VSfP2MflxOv5-8inoGj4EEv2OTSCE4IlKMykKw1giTWFyRiNETaF1qjMlqcoSmcmQKiYjaqLQJKnKOeNKKhXTI3JY21o_JZBK3GlyHMpNkcQq4SJDUIbGcZtwzQkHJOr1XsquGrpryrEo_a6IZWWrpxL1VHo9lfmAvNv9Z9XWArl29AcHp91IV8fb_2DX87JbFso00YYmuaCpRhmNYZLxkLtYK0It1ijmqx6MJc57F8xB1dttU7qIOXr3LMwG5EkLzt2lKO4DizhKBiTfg-2eLPtH6urC1xbP04wx93hGPXjLblFrrrnXZ_82_Dm5Ezv8u8Sg_AU53Ky3-iW5JX9uqmY9JAf5jA39nB76VyS_AVpoSF0 |
| linkProvider | Springer Nature |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BQcCF9yM8B4kDqFnJb6-5lSqlEWlAqES9rfaZWkrsKE449D_yn5hdO5ECVSW4xcnaHnu-3ZnNzHxDyLs0sAErmKZ5YAKapExREdqIqthKIZTRoe91OBnl4zE7Oyu-dUVhzSbbfROS9Cu1n9Ysc8VuoaOxjVwilSuAzq-TG456xeH60NU4dNssF-vyLVWigkZxVmxKZS69xo458qz9l7maf2dM_hE29dbo6N7_Pcd9crfzPuGghcsDcs1UD8mtky6-_oj8GvqiSagtoOXAt24u1nMhoa5gVaObDgtRViB96cNH8PHuatqAq1GBxTkaRIgBjZ-u5-WF0X3Q9VrODJUoJx75_C9Z0y49fmY0NG0aI-BVO4bXBtxfw2AWZVOjWFAvQbUEvjAvp66hhYH3g8nX0WRAwz50n6I-4G3h--DzwXAMvhVJ8-Ex-XE0OD08pl3DB6rQ71hRKaVIdJopWVjGEmULm7M4RNQUxqQm0yrWWaIyFcSaqTC2YWCTVOeCCa20juInZK-qK_OMQKpwpylwqLBFEulEyAxBGVhX24RrTtAj4UbvXHVs6K4px4z7XRHLeKsnjnriXk8875H97TmLlgvkytGfHJy2Ix2Pt_-iXk55tyzwNDE2TnIZpwZltJYpJgLhYq0ItcigmG83YOQ4710wB1VfrxvuIubo3bMg65GnLTi3t4pxH1hEYdIj-Q5sd2TZ_aUqzz23eJ5mjLnX09-Al3eLWnPFsz7_t-FvyO3j05MRHw3HX16QO5GbCy5JKH9J9lbLtXlFbqqfq7JZvvYz-zdYU0ll |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgQSsuvB_lOUgcQNQi7zjclqULFaWsEFR7s_zsRmqTqmk57H_kPzF20orCaiXErWmdZNL5bM9k5psh5EUa2IAVTNM8MAFNUqaoCG1EVWylEMro0Pc6nIzy8ZidnBTHv7H4fbb7JiTZchpclaZq9WahbTvFWeaIb6EraRu5pCpHhs4vkysuIuXcr0PHd-hcLhf38u1VooJGcVZsaDPnXmNna_IV_M8zO__OnvwjhOp3pqMb__9MN8n1ziqFgxZGt8glU90m-5-7uPsd8nPoyZRQW8AdBbVhztZzIaGuYFWj-Q4LUVYgPSXiLfg4eDVtwHFXYHGKGyXEgJuiruflmdF90PVazgyVKDMe-bwwWdMubX5mNDRteiPgVbvKrw24V8ZgFmVTo1hQL0G1hX1hXk5dowsDLweTL6PJgIZ96D5FfcDbwtfBh4PhGHyLkubVXfL9aPDt8CPtGkFQhfbIikopRaLTTMnCMpYoW9icxSGiqTAmNZlWsc4Slakg1kyFsQ0Dm6Q6F0xopXUU3yN7VV2ZBwRShR6owKHCFkmkEyEzBGtgHecJ16KgR8INBrjqqqS7Zh0z7r0llvFWTxz1xL2eeN4jr7fnLNoaIReOfuegtR3p6nv7L-rllHfLBU8TY-Mkl3FqUEZrmWIiEC4Gi7CLDIr5fANMjuuBC_Kg6ut1w10kHa1-FmQ9cr8F6vZWMfqHRRQmPZLvQHhHlt1fqvLU1xzP04wx9_f0N0Dm3WLXXPCsD_9t-DOyf_z-iI-G40-PyLXITQWXO5Q_Jnur5do8IVfVj1XZLJ_6Sf4LVlhSSQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+galcanezumab+on+total+pain+burden%3A+findings+from+phase+3+randomized%2C+double-blind%2C+placebo-controlled+studies+in+patients+with+episodic+or+chronic+migraine+%28EVOLVE-1%2C+EVOLVE-2%2C+and+REGAIN+trials%29&rft.jtitle=Journal+of+headache+and+pain&rft.au=Ailani%2C+Jessica&rft.au=Andrews%2C+J+Scott&rft.au=Rettiganti%2C+Mallikarjuna&rft.au=Nicholson%2C+Robert+A&rft.date=2020-10-17&rft.eissn=1129-2377&rft.volume=21&rft.issue=1&rft.spage=123&rft_id=info:doi/10.1186%2Fs10194-020-01190-7&rft_id=info%3Apmid%2F33069214&rft.externalDocID=33069214 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1129-2369&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1129-2369&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1129-2369&client=summon |